vaccin à vecteur

DOM: pandémie de COVID-19; EXP: par ex. les vaccins contre le COVID-19 d'AstraZeneca et de Johnson & Johnson; ces vaccins sont basés sur un adénovirus humain (virus du rhume humain) qui contient le plan de construction de la protéine Spike du coronavirus SARS-CoV-2, déclencheur de la réponse immunitaire souhaitée contre le virus dans les cellules immunitaires humaines

Source : Swissmedic, Comm. pr. Vaccin contre le COVID-19 de Johnson & Johnson: Swissmedic autorise un troisième vaccin contre le COVID-19, 2021-03-22 ([Internet, 2021-03-26](https://www.edi.admin.ch/edi/fr/home/documentation/communiques-de-presse.msg-id-82783.html))

Source : OFSP, Voici comment nous protéger:, Comment fonctionne la vaccination?, 2021-03-10 ([Internet, 2021-03-19](https://ofsp-coronavirus.ch/vaccination/comment-fonctionne-la-vaccination/))

DOM: Covid-19-Pandemie; EXP: z. B. Covid-19-Impfstoffe von AstraZeneca und Johnson & Johnson; diese Impfstoffe basieren auf einem humanen Adenovirus (menschliches Schnupfenvirus), das den Bauplan der Spike-Proteine des Coronavirus SARS-CoV-2 enthält, auf deren Grundlage in den menschlichen Immunzellen die gewünschte Immunantwort gegen das Virus ausgelöst wird

Source : Swissmedic, MM Covid-19 Impfstoff von Johnson & Johnson: Swissmedic genehmigt den dritten Impfstoff gegen eine Covid-19 Erkrankung, 2021-03-22 ([Internet, 2021-03-26](https://www.edi.admin.ch/edi/de/home/dokumentation/medienmitteilungen.html.msg-id-82783.html))

Source : Robert Koch-Institut, Epidemiologisches Bulletin, 2/2021, S. 22, Ziff. 7.2

Source : BAG, MM COVID-19-Impfstoff: Bund unterzeichnet Vertrag mit AstraZeneca, 2020-10-16 ([Internet, 2021-03-19](https://www.bag.admin.ch/bag/de/home/das-bag/aktuell/medienmitteilungen.msg-id-80732.html))

DOM: pandemia di COVID-19; EXP: per es. i vaccini anti-COVID-19 di AstraZeneca e Johnson & Johnson; in questi vaccini, il vettore è un adenovirus umano (variante umana del virus del raffreddore) che contiene la struttura delle proteine spike del coronavirus SARS-CoV-2, sulle cui basi viene attivata la risposta immunitaria desiderata contro il virus nelle cellule immunitarie umane

Source : UFSP, Così ci proteggiamo, Come agisce la vaccinazione?, 2021-03-10 ([Internet, 2021-03-19](https://ufsp-coronavirus.ch/vaccinazione/come-agisce-la-vaccinazione/))

Source : IT, Istituto superiore di sanità ISS, Come funziona un vaccino a vettore virale?, 2021-03-16 ([Internet, 2021-05-20](https://www.iss.it/covid19-faq/-/asset_publisher/yJS4xO2fauqM/content/come-funziona-un-vaccino-a-vettore-virale-))

DOM: COVID-19 pandemic

Source : Carnall Farrar, The race for the COVID-19 vaccine: A story of innovation and collaboration, 2020-11 ([Internet, 2021-03-18](http://carnallfarrar.co.uk/articles/the-race-for-the-covid-19-vaccine-a-story-of-innovation-and-collaboration/))

Source : Centers for Disease Control and Prevention, Understanding Viral Vector COVID-19 Vaccines, 2021-03-02 ([Internet, 2021-03-18](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.html))

Source : FOPH, PR COVID-19 vaccine: Swiss federal government signs agreement with AstraZeneca, 2020-10-16 ([Internet, 2021-03-19](https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-80732.html))

DOM: pandemia da COVID-19; EXP: p.ex. ils vaccins cunter COVID-19 d'AstraZeneca e Johnson & Johnson; quests vaccins sa basan sin in adenovirus uman (virus da dafraid uman) che cuntegna in plan da construcziun dals proteins spike dal coronavirus SARS-CoV-2, sin basa dals quals la resposta immunitara giavischada encunter il virus vegn activada en las cellas immunitaras umanas

Source : Chanzlia chantunala dal Grischun, Servetsch da translaziuns, 2021